Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia-Reference-Cited by-同舟云学术

Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia

Published:2015-09-16 Issue:3 Volume:30 Page:708-715
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Zeijlemaker W,Kelder A,Oussoren-Brockhoff Y J M,Scholten W J,Snel A N,Veldhuizen D,Cloos J,Ossenkoppele G J,Schuurhuis G J

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015255.pdf

Reference41 articles.

1. Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Vekemans M-C et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood 2012; 119: 5367–5373.

2. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642–4649.

3. Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013; 31: 4123–4131.

4. Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42 A study. J Clin Oncol 2013; 31: 3889–3897.

5. Shayegi N, Kramer M, Bornhauser M, Schaich M, Schetelig J, Platzbecker U et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood 2013; 122: 83–92.

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

2. Measurable residual disease (MRD)-testing in haematological and solid cancers;Leukemia;2024-04-18

3. Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions;Biomedicines;2024-03-07

4. Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia;Leukemia;2024-01-25

5. Measurable Residual Disease Assessment in Pediatric AML;Pediatric Oncology;2024